aspirin /d

ApprovedSmall molecule

TThe First Affiliated Hospital with Nanjing Medical University

aspirin /d is one of 197 small molecule programs targeting Aneurysm. It is currently in Approved.

Indications

Total Trials

Active Trials

196

Competitors

Pipeline

Status by Indication[3][1]

Indication

AneurysmActive, not recruiting

Coronary AtherosclerosisActive, not recruiting

CognitionActive, not recruiting

Peripheral Arterial DiseaseActive, not recruiting

MigraineActive, not recruiting

Atrial FibrillationActive, not recruiting

AneurysmApproved

Active, not recruiting

Coronary AtherosclerosisApproved

Active, not recruiting

CognitionPhase 2

Active, not recruiting

Peripheral Arterial DiseaseApproved

Active, not recruiting

MigrainePhase 3

Active, not recruiting

Atrial FibrillationApproved

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

aspirin /d

TThe First Affiliated Hospital with Nanjing Medical University

Approved

1 2

Calquence

AstraZeneca

Preclinical

1 3

Brukinsa

BBeOne Medicines

Preclinical

1 4

Imbruvica

PPharmacyclics LLC.

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 8

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Anticoagulants

Sanofi

Preclinical

2 10

Calcium

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antiplatelet Therapy2 trials

the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT03230851·210 enrolled

Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events

Completed·SSeung-Jung Park·Phase 4·NCT02939872·238 enrolled

Coronary Atherosclerosis1 trial

A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05105750·60 enrolled

Platelet Reactivity1 trial

Platelet Reactivity in PAD Undergoing Percutaneous Angioplasty

Unknown status·CClinical Centre of Serbia··NCT04165629·450 enrolled

Atrial Appendage1 trial

Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05671276·150 enrolled

Anticoagulation1 trial

Anticoagulation in Blunt Cerebrovascular Injuries

Withdrawn·—·N/A·NCT00494156

10 more indications

Drug1 trial

Anti-Platelet Drugs and Brain-derived Neurotrophic Factor (BDNF) in Human Serum and Plasma

Unknown status·UUniversity of Rostock·N/A·NCT01264640·25 enrolled

Atrial Fibrillation1 trial

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

Unknown status·SScripps Health·Phase 4·NCT03088072·75 enrolled

ISS1 trial

VISSIT Intracranial Stent Study for Ischemic Therapy

Terminated·CCodman & Shurtleff·Phase 2/3·NCT00816166·125 enrolled

Complication1 trial

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active, not recruiting·PPetrovsky National Research Centre of Surgery··NCT07358416·500 enrolled

Migraine1 trial

Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine

Active, not recruiting·GGuangdong Provincial People's Hospital·Phase 3·NCT04946734·440 enrolled

Aneurysm1 trial

Study of Antiplatelet Therapy for Intracranial Aneurysm Stent-assisted Coiling

Unknown status·—·Phase 4·NCT02224131·1,856 enrolled

Dual Antiplatelet Therapy1 trial

Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT00822536·1,798 enrolled

Cognition1 trial

NeuroCognition After Carotid Recanalization

Completed·—·Phase 2·NCT04219774·25 enrolled

Peripheral Arterial Disease1 trial

Ticagrelor and Peripheral Arterial Disease

Terminated·—·Phase 4·NCT02407314·26 enrolled

Unspecified2 trials

Ticagrelore Alone Post PCI

Recruiting·SShiraz University of Medical Sciences·Phase 4·NCT06509893·5,400 enrolled

Reversal of the Anti-platelet Effects of Ticagrelor

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT02383771·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for aspirin /d. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — aspirin /d compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for aspirin /d. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital with Nanjing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe First Affiliated Hospital with Nanjing Medical University

aspirin /d

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Antiplatelet Therapy2 trials

Coronary Atherosclerosis1 trial

Platelet Reactivity1 trial

Atrial Appendage1 trial

Anticoagulation1 trial

Drug1 trial

Atrial Fibrillation1 trial

ISS1 trial

Complication1 trial

Migraine1 trial

Aneurysm1 trial

Dual Antiplatelet Therapy1 trial

Cognition1 trial

Peripheral Arterial Disease1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News